The Emergence of COVID-19 to Augment Growth of the Immunoglobulin Market

 

Immunoglobulin Market

Immunoglobulins are used by the body's immune system to safely identify and target foreign objects like viruses and pathogenic bacteria. Immunoglobulin recognizes a unique substance of the pathogen, termed antigens. When introduced into the body, the immunoglobulin immediately targets antigens and destroys them. Since antibodies are made up of molecules of different sizes and shapes, immunoglobulin is able to bind to many different molecules at once.

Immunoglobulin are used to treat autoimmune diseases such as autoimmune haemolytic anemia, immune thrombocytopenia purpura, primary humoral immunodeficiency, and multiple sclerosis. Moreover, immunoglobulin has a wide variety of applications in rheumatology, nephrology, ophthalmology, dermatology, immunology, neurology, and hematology.

Market Dynamics:

Increase in research and development, increase in clinical trials, and increasing number of intravenous product approvals is expected to propel the growth of the immunoglobulin market. For instance, in 2018, ADMA Biologics received U.S. patent (valid till January 2035) for the treatment of respiratory infection. The patent consist of usage of polyclonal immunoglobulin preparation for the treatment of respiratory infection.

Moreover, increasing prevalence of autoimmune diseases, growing use of immunoglobulin in various therapeutic areas, and growing geriatric population is also expected to augment the growth of the immunoglobulin market.

The emergence of COVID-19 is expected to offer lucrative growth opportunities for players in the immunoglobulin market. For instance, in December 2020, the National Center for Global Health and Medicine (NCGM) and Fujita Health University launched an investigator-led study to assess the safety and efficacy of immunoglobulin for COVID-19 as part of a global trial led by the National Institutes of Health (NIH).

Competitive Analysis:

Major players operating in the immunoglobulin market are LFB group, Biotest AG, CSL Ltd., Octapharma AG, Grifols S.A, BioScrip, Inc. ADMA Biologics, Inc., Option Care Enterprises, Inc., Shanghai RAAS Blood Products Co., Ltd., Behring GmbH, Omrix Biopharmaceuticals Ltd., Hualan Biological Engineering Inc., Bayer Healthcare BDI Pharma Inc., China Biologics Products, Inc., Kedrion Biopharma Inc., and Baxter international Inc.

Major players in the market are involved in research and development to develop new immunoglobulin drugs. For instance, in February 2021, Evolve Biologics Inc. successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin). PlasmaCap IG (IVIG) is an investigational IVIG replacement therapy for adult and pediatric patients with primary immune deficiency disease (PIDD).

In March 2018, Euro-Atlantic Disaster Response Coordination Centre (EADRCC) launched an urgent request for supplies of human immunoglobulin in response to a request from Romania.